Elevation of alkaline phosphatase in a pregnant patient with antiphospholipid syndrome: HELLP syndrome or not?
SIR, Pregnant patients with APS may develop HELLP syndrome (haemolysis; elevated liver enzymes; low platelet count) that can manifest first by elevation of ALP level. However, other causes of ALP elevation must be discussed and include elevation of ALP of placental origin. We report for the first time an APS pregnant patient presenting with ALP increased over 15-fold of placental origin.
A 40-yr-old patient with an APS was followed for her fifth pregnancy. Past obstetrical history included a normal pregnancy followed by two foetal deaths at 18 weeks of gestation (WG) and a spontaneous abortion at 8 WG. Repeated searches for aCL antibodies were positive. ANA were negative. Her clinical history was otherwise unremarkable. A diagnosis of primary obstetrical APS was made according to the usual criteria [1] .
She was treated with aspirin and low molecular weight heparin (enoxaparin 0.4 ml twice a day). At 19 WG, serum ALP level was 200 U/l (normal values: 40-120). She had neither hypertension nor oedema. Results of other liver function tests, blood cell counts and urine tests were normal. Liver ultrasonographic examination was normal. During follow-up, as the patient remained symptom free, ALP increased and reached 1722 U/l at 36 WG without other biochemical abnormality. Obstetrical ultrasonographic examination and Doppler blood flow remained normal.
Rheumatology key message
Patients with KFD should receive periodical follow-up for several years to detect possible evolution of SLE.
At that time, given the absence of any clinical or biochemical abnormalities suggestive of HELLP syndrome, an isolated placental ALP elevation was suspected. Serum ALP electrophoresis showed normal ALP level of liver (57 U/l) and bone (146 U/l) origin, whereas placental isozyme 1 ALP was 1054 U/l and placental isozyme 2 ALP was 465 U/l.
She delivered a healthy newborn of 2560 g at 37 WG. The placenta was normal and weighed 435 g. Serum ALP level was 216 U/l at 4 weeks post-partum and normal at 5 weeks post-partum (Fig. 1) .
ALP is an enzyme produced by liver, bones, kidneys, small intestine and placenta. In a pregnant patient, elevation of ALP may be related to HELLP syndrome, intrahepatic cholestasis, malignancy and liver or bone diseases. However, a placental origin of ALP must also be discussed.
ALP is physiologically produced by placenta at the brush border membranes of the syncytiotrophoblast [2] . It appears in maternal serum between the 15th and the 26th WG [3] and increases during the third trimester [4] . Usually, ALP production or diffusion in maternal serum is not major and total serum ALP level remains normal. Some cases of unusual elevation of placental ALP have been described [2, [5] [6] [7] . The mechanism of serum placental ALP increase is not well understood. A genetic abnormality has been suspected in one case [6] and a link with a risk of pre-term delivery has been discussed [7] .
Our case is the first described in a patient with APS and we did not observe any other cases among more than 200 pregnant patients with APS followed in our centre. In this setting, ALP electrophoresis can be useful to distinguish placental from hepatic or bone isozymes. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA) SIR, Systemic onset juvenile idiopathic arthritis (SOJIA) accounts for $10-20% of all patients with JIA, but it accounts for increased morbidity and mortality compared with other forms of JIA [1] . A significant number of patients have ongoing disease activity despite aggressive treatment. A follow-up study found that the probability of disease remission 10 yrs after onset was only 37% [2] . Despite a variety of treatments some children with SOJIA have a refractory course with significant morbidity. Pasqual et al. [3] have published data indicating that IL-1 is a major mediator of the inflammatory cascade that underlies SOJIA, and that this cytokine represents a target for therapy in this disease. Anakinra is a recombinant form of human IL-1 receptor antagonist that inhibits activity of IL-1. Recently, case reports using anakinra have suggested efficacy in refractory SOJIA [4, 5] . We report our experience with anakinra in three centres in the UK.
Data were collected from three tertiary paediatric rheumatology centers in the UK on all their patients with SOJIA who had received anakinra. Seven patients were identified. ILAR classification was used to establish SOJIA diagnosis in all centers [6] . Data were retrospectively collected by case notes review of the seven patients using data collection sheets. Age at diagnosis, age at starting anakinra and all previously failed medications were recorded. Core set, clinical and laboratory findings were recorded prior to starting anakinra and at 1, 3, 6 and 12 months after starting anakinra. Serious infections, adverse events and injection site reactions were also recorded.
The median age at diagnosis of SOJIA was 5.3 yrs (range 2.1-14 yrs). The median age at starting anakinra was 8.5 yrs (range 5.2-15 yrs). The median follow-up time from starting anakinra was 1 yr (range 0.75-2.3 yrs). Previous failed treatments included methotrexate (n ¼ 6), cyclosporin (n ¼ 4), immunoglobulin (n ¼ 5), etanercept (n ¼ 2) and infliximab (n ¼ 2). Four patients had active
Placental alkaline phosphatase elevation can be independent of APS during pregnancy. 
